메뉴 건너뛰기




Volumn 3, Issue 1, 2006, Pages 2-3

Clinical management of BRCA1 and BRCA2 mutation carriers

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLATINUM DERIVATIVE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

EID: 30944448279     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0384     Document Type: Review
Times cited : (7)

References (13)
  • 1
    • 0037162110 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    • Rebbeck TR et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616-1622
    • (2002) N Engl J Med , vol.346 , pp. 1616-1622
    • Rebbeck, T.R.1
  • 2
    • 0037162115 scopus 로고    scopus 로고
    • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    • Kauff ND et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609-1615
    • (2002) N Engl J Med , vol.346 , pp. 1609-1615
    • Kauff, N.D.1
  • 3
    • 0032514413 scopus 로고    scopus 로고
    • Oral contraceptives and the risk of hereditary ovarian cancer
    • Narod SA et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424-428
    • (1998) N Engl J Med , vol.339 , pp. 424-428
    • Narod, S.A.1
  • 4
    • 0037021659 scopus 로고    scopus 로고
    • Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    • Narod SA et al. (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94: 1773-1779
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1773-1779
    • Narod, S.A.1
  • 5
    • 30944463691 scopus 로고    scopus 로고
    • Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
    • Rebbeck TR et al. (2005) Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 23: 7804-7810
    • (2005) J Clin Oncol , vol.23 , pp. 7804-7810
    • Rebbeck, T.R.1
  • 6
    • 1842867053 scopus 로고    scopus 로고
    • Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial
    • Anderson GL et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712
    • (2004) JAMA , vol.291 , pp. 1701-1712
    • Anderson, G.L.1
  • 7
    • 0035913275 scopus 로고    scopus 로고
    • Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
    • Meijers-Heijboer H et al. (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345: 159-164
    • (2001) N Engl J Med , vol.345 , pp. 159-164
    • Meijers-Heijboer, H.1
  • 8
    • 0034597916 scopus 로고    scopus 로고
    • Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
    • Narod SA et al. (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356: 1876-1881
    • (2000) Lancet , vol.356 , pp. 1876-1881
    • Narod, S.A.1
  • 9
    • 0035861037 scopus 로고    scopus 로고
    • Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial
    • King MC et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251-2256
    • (2001) JAMA , vol.286 , pp. 2251-2256
    • King, M.C.1
  • 10
    • 4544230001 scopus 로고    scopus 로고
    • Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination
    • Warner E et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292: 1317-1325
    • (2004) JAMA , vol.292 , pp. 1317-1325
    • Warner, E.1
  • 11
    • 0034306318 scopus 로고    scopus 로고
    • Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations
    • Pierce LJ et al. (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18: 3360-3369
    • (2000) J Clin Oncol , vol.18 , pp. 3360-3369
    • Pierce, L.J.1
  • 12
    • 3042780235 scopus 로고    scopus 로고
    • Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients
    • Schwartz MD et al. (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22: 1823-1829
    • (2004) J Clin Oncol , vol.22 , pp. 1823-1829
    • Schwartz, M.D.1
  • 13
    • 17244373777 scopus 로고    scopus 로고
    • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • Farmer H et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921
    • (2005) Nature , vol.434 , pp. 917-921
    • Farmer, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.